# Pulse Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pulse-therapeutics

- Industry: Medical Devices & Equipment
- Headquarters: St. Louis, US
- Website: www.pulsetherapeutics.com
- Total disclosed funding: $5.7M
- Latest round: Series B (Apr 23, 2012)
- Investors on record: 5

## About

Pulse Therapeutics, Inc. is a medical technology company that specializes in developing advanced solutions for vascular occlusions, focusing on innovative therapies to enhance patient outcomes in critical medical situations.Pulse Therapeutics, Inc. was founded in 2008 and is headquartered in St. Louis, US. The company develops interventional tools for treating complex vascular conditions. Rogers Ritter is the founder, and James Wachtman is the current CEO. The company has raised a total of USD 10.00 mn, most recently in January 2016, with participation from investors including +ND Capital and Cultivation Capital, focusing on improving their medical device offerings.Pulse Therapeutics, Inc. is known for its Pulse NanoMED™ System, an advanced medical device designed to address distal vascular occlusions. Utilizing iron-oxide nanoparticles, guided by a rotating magnet, this system effectively treats conditions like Acute Ischemic Stroke, ST-Elevation Myocardial Infarction, and Critical Limb Threatening Ischemia. The company primarily serves healthcare facilities and interventional physicians in North America and Europe, providing targeted solutions for complex vascular interventions.Revenue for Pulse Therapeutics is generated from the sale of its Pulse NanoMED™ System to hospitals and healthcare providers. The company engages in direct sales and partnerships with distributors, focusing on interventional cardiologists and neurologists. Their pricing strategy aligns with healthcare budgets while reflecting the technological advancements of their products, aiming to improve patient outcomes and reduce hospitalization times.Pulse Therapeutics plans to utilize the recent funding of USD 10.00 mn raised in January 2016 to support the development of new products and expand its market reach. The company is designing additional features for the Pulse NanoMED™ System and intends to enter new geographic markets in North America and Europe by 2025, targeting healthcare facilities dealing with acute vascular conditions.

## Funding rounds

- Series B, Apr 23, 2012, $3.1M — BioGenerator
- Series A, Mar 18, 2011, $2M — Lewis & Clark Capital
- Seed, Aug 11, 2010, $0.6M — BioGenerator, Skandalaris Student Venture Fund, Missouri Technology Corporation, Integrated Magnetics

## Investors

- BioGenerator (https://capitalatlas.ai/funds/biogenerator) — Seed, Series B
- Skandalaris Student Venture Fund — Seed
- Missouri Technology Corporation — Seed
- Integrated Magnetics — Seed
- Lewis & Clark Capital (https://capitalatlas.ai/funds/lewis-clark-capital) — Series A